CR20200211A - Derivados de piridinona y uso como inhibidores selectivos de alk-2 - Google Patents

Derivados de piridinona y uso como inhibidores selectivos de alk-2

Info

Publication number
CR20200211A
CR20200211A CR20200211A CR20200211A CR20200211A CR 20200211 A CR20200211 A CR 20200211A CR 20200211 A CR20200211 A CR 20200211A CR 20200211 A CR20200211 A CR 20200211A CR 20200211 A CR20200211 A CR 20200211A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
pyridinone derivatives
selective alk
alk
selective
Prior art date
Application number
CR20200211A
Other languages
English (en)
Inventor
Sven Weiler
Mika Lindvall
Pier Luca D'ALESSANDRO
Sylvie Teixeira-Fouchard
Sylvie Chamoin
Nikolaus Johannes Stiefl
Thomas Ullrich
Luca Arista
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20200211A publication Critical patent/CR20200211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a un compuesto de Fórmula I o una de sus sales farmacéuticamente aceptables, un método para la fabricación de los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
CR20200211A 2017-11-24 2017-11-24 Derivados de piridinona y uso como inhibidores selectivos de alk-2 CR20200211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/057389 WO2019102256A1 (en) 2017-11-24 2017-11-24 Pyridinone derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
CR20200211A true CR20200211A (es) 2020-06-19

Family

ID=60702886

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200211A CR20200211A (es) 2017-11-24 2017-11-24 Derivados de piridinona y uso como inhibidores selectivos de alk-2

Country Status (24)

Country Link
US (1) US11160797B2 (es)
EP (1) EP3713927B1 (es)
JP (1) JP7091455B2 (es)
KR (1) KR20200091422A (es)
CN (1) CN111433195B (es)
AU (1) AU2017440306B2 (es)
BR (1) BR112020010171A2 (es)
CA (1) CA3081651A1 (es)
CL (1) CL2020001277A1 (es)
CO (1) CO2020005885A2 (es)
CR (1) CR20200211A (es)
CU (1) CU20200035A7 (es)
DO (1) DOP2020000088A (es)
EA (1) EA202091293A1 (es)
EC (1) ECSP20026023A (es)
ES (1) ES2908252T3 (es)
IL (1) IL274722A (es)
JO (1) JOP20200127A1 (es)
MX (1) MX2020005405A (es)
PE (1) PE20201282A1 (es)
PH (1) PH12020550763A1 (es)
RU (1) RU2020120538A (es)
SG (1) SG11202003920QA (es)
WO (1) WO2019102256A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
US20220401445A1 (en) * 2020-04-30 2022-12-22 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
CN113354631B (zh) * 2021-06-01 2022-11-18 江苏大学 一种1,3,4-噁二唑衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332779T2 (de) 1992-11-17 2003-10-23 Ludwig Institut For Cancer Research, Padington Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
AU2007292890A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US20100093760A1 (en) 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
RU2017112518A (ru) * 2010-05-07 2019-01-25 Джилид Коннектикут, Инк. Пиридоновые и азапиридоновые соединения и способы применения
MX2013001977A (es) 2010-08-20 2013-04-03 Wyeth Llc Proteinas osteogenicas de diseño.
AU2011340167A1 (en) 2010-12-06 2013-07-18 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
PL3321262T3 (pl) 2012-03-01 2021-06-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
US20170190705A1 (en) 2014-03-26 2017-07-06 The Brigham And Woman's Hospital, Inc. Compositions and Methods for Inhibiting BMP
US20170305883A1 (en) * 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
AU2016249537B2 (en) * 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives

Also Published As

Publication number Publication date
US11160797B2 (en) 2021-11-02
AU2017440306A1 (en) 2020-05-21
CN111433195A (zh) 2020-07-17
RU2020120538A (ru) 2021-12-24
CU20200035A7 (es) 2021-03-11
IL274722A (en) 2020-07-30
BR112020010171A2 (pt) 2020-11-03
JP7091455B2 (ja) 2022-06-27
EP3713927A1 (en) 2020-09-30
ES2908252T3 (es) 2022-04-28
CL2020001277A1 (es) 2020-11-13
JP2021512850A (ja) 2021-05-20
MX2020005405A (es) 2020-08-13
RU2020120538A3 (es) 2021-12-24
SG11202003920QA (en) 2020-06-29
AU2017440306B2 (en) 2021-01-28
JOP20200127A1 (ar) 2020-05-21
DOP2020000088A (es) 2020-08-31
PE20201282A1 (es) 2020-11-24
EP3713927B1 (en) 2021-12-15
CO2020005885A2 (es) 2020-07-31
US20200360357A1 (en) 2020-11-19
CA3081651A1 (en) 2019-05-31
CN111433195B (zh) 2023-04-25
KR20200091422A (ko) 2020-07-30
PH12020550763A1 (en) 2021-04-26
EA202091293A1 (ru) 2020-11-23
ECSP20026023A (es) 2020-07-31
WO2019102256A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2016014946A (es) Derivados de carboxamida.
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
PH12016502247A1 (en) Carboxamide derivatives